United Health Services (UHS)

nyuhs.org

United Health Services (UHS) is the largest comprehensive healthcare system and leading private employer in the Greater Binghamton, N.Y., region. With more than 60 locations in Broome and surrounding counties, the system is composed of providers and supporting organizations serving the 600,000 residents of the Southern Tier of upstate New York and portions of Northeast Pennsylvania. A locally owned, 916-bed, not-for-profit system, it is governed by a Board of Directors made up of community citizens who volunteer their time. The employees, providers, volunteers and leadership of UHS share a commitment and promise to the people whom they serve: We will listen. We will show respect. We will give hope.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

LIFEMINE THERAPEUTICS AND GSK ENTER DRUG DISCOVERY AND DEVELOPMENT ALLIANCE

LifeMine | March 28, 2022

news image

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced a strategic R&D collaboration with GlaxoSmithKline (GSK). The collaboration will provide GSK with access to LifeMine’s genomically enabled drug discovery platform to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease areas. Under the te...

Read More

LOGICBIO ROCKED BY FDA CLINICAL HOLD ON GENOME EDITING TRIAL

FierceBiotech | February 11, 2020

news image

The FDA has placed a clinical hold on LogicBio Therapeutics’ planned genome editing trial. LogicBio wants to trial the therapy in methylmalonic acidemia (MMA) patients aged two years and up but has run into resistance at the FDA. Details of the nature of the regulatory resistance and how soon it is likely to be resolved are scarce. LogicBio provided scant information in its statement to disclose the FDA clinical hold. According to analysts at Jefferies who spoke to management at LogicBio, ...

Read More

WITH AN EYE ON THE CLINIC, ATLAS-BACKED KYMERA SECURES $102 MILLION

BioSpace | March 12, 2020

news image

Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology. Kymera's lead program targets IRAK4, a protein that is known to play a significant role in inflammation that is mediated by toll-like and IL-1 receptors. Kymera aims to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine ta...

Read More

MEDTECH

SORRENTO ANNOUNCES COVISTIX COVID-19 VIRUS RAPID ANTIGEN DETECTION TEST DETECTS THE OMICRON VARIANT

Sorrento Therapeutics, Inc. | December 28, 2021

news image

Sorrento Therapeutics, Inc. announced that initial testing of COVISTIX on recombinant N proteins demonstrated its ability to detect the Omicron variant, in addition to detecting the original SARS-CoV-2 virus and its other major VoCs such as the delta and delta-plus strains. The COVISTIX detection levels were similar for all variants. The ease of use and timely detection of Omicron infection was demonstrated by a recent case report of a Mexico patient infected with the Omicron variant detected fi...

Read More
news image

LIFEMINE THERAPEUTICS AND GSK ENTER DRUG DISCOVERY AND DEVELOPMENT ALLIANCE

LifeMine | March 28, 2022

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced a strategic R&D collaboration with GlaxoSmithKline (GSK). The collaboration will provide GSK with access to LifeMine’s genomically enabled drug discovery platform to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease areas. Under the te...

Read More
news image

LOGICBIO ROCKED BY FDA CLINICAL HOLD ON GENOME EDITING TRIAL

FierceBiotech | February 11, 2020

The FDA has placed a clinical hold on LogicBio Therapeutics’ planned genome editing trial. LogicBio wants to trial the therapy in methylmalonic acidemia (MMA) patients aged two years and up but has run into resistance at the FDA. Details of the nature of the regulatory resistance and how soon it is likely to be resolved are scarce. LogicBio provided scant information in its statement to disclose the FDA clinical hold. According to analysts at Jefferies who spoke to management at LogicBio, ...

Read More
news image

WITH AN EYE ON THE CLINIC, ATLAS-BACKED KYMERA SECURES $102 MILLION

BioSpace | March 12, 2020

Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology. Kymera's lead program targets IRAK4, a protein that is known to play a significant role in inflammation that is mediated by toll-like and IL-1 receptors. Kymera aims to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine ta...

Read More
news image

MEDTECH

SORRENTO ANNOUNCES COVISTIX COVID-19 VIRUS RAPID ANTIGEN DETECTION TEST DETECTS THE OMICRON VARIANT

Sorrento Therapeutics, Inc. | December 28, 2021

Sorrento Therapeutics, Inc. announced that initial testing of COVISTIX on recombinant N proteins demonstrated its ability to detect the Omicron variant, in addition to detecting the original SARS-CoV-2 virus and its other major VoCs such as the delta and delta-plus strains. The COVISTIX detection levels were similar for all variants. The ease of use and timely detection of Omicron infection was demonstrated by a recent case report of a Mexico patient infected with the Omicron variant detected fi...

Read More